Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new paradigm for plaque stabilization.

John A Ambrose1, Eulogio E Martinez

  • 1Comprehensive Cardiovascular Center, Department of Medicine, Saint Vincent Catholic Medical Centers of New York, NY 10011, USA. jambrose@saintvincentsnyc.org

Circulation
|May 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Takotsubo - The great pretender.

International journal of cardiology·2025
Same author

Time to Tweak the Definition of Type 2 Myocardial Infarction.

The American journal of cardiology·2024
Same author

Artificial Intelligence and the Doctor-Patient Relationship.

The American journal of medicine·2024
Same author

Identifying and Treating Vulnerable Atherosclerotic Plaques.

The American journal of cardiology·2023
Same author

In Search of Coronary Thrombosis as the Cause of Myocardial Infarction: Unraveling a 20th-Century Mystery.

The American journal of medicine·2022
Same author

New Precordial T Wave Inversions in Hospitalized Patients.

The American journal of medicine·2021
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
See all related articles

Plaque stabilization, primarily through lipid lowering, reduces coronary events by improving vessel wall health. However, this concept needs expansion to address destabilized and non-lipid-rich plaques for comprehensive cardiovascular event prevention.

Area of Science:

  • Cardiovascular Medicine
  • Atherosclerosis Research
  • Pharmacology

Background:

  • The concept of plaque stabilization explains how lipid-lowering therapies reduce adverse coronary events without significant atherosclerosis regression.
  • Lipid lowering induces favorable pathobiological changes in lipid-rich plaques, which are a major cause of acute coronary events.

Purpose of the Study:

  • To evaluate the limitations of the plaque stabilization concept.
  • To explore therapeutic strategies for both destabilized and non-lipid-rich plaques.
  • To identify mechanisms by which various therapies reduce future acute coronary events.

Main Methods:

  • Review of existing literature on plaque stabilization and cardiovascular event reduction.
  • Analysis of therapeutic approaches including lipid lowering, percutaneous intervention, antithrombotic, and anticoagulant therapies.

Related Experiment Videos

  • Examination of the role of ACE inhibitors and beta-blockers in plaque stabilization.

    • Main Results:

    • The plaque stabilization concept is limited as it doesn't fully address already destabilized plaques or non-lipid-rich plaques.
    • Destabilized plaques with thrombus may benefit from percutaneous intervention, antithrombotics, anticoagulants, or aggressive lipid lowering.
    • Therapies like ACE inhibitors, beta-blockers, and antithrombotics may reduce events partly through plaque-stabilizing effects.

    Conclusions:

    • The plaque stabilization concept requires refinement to encompass a broader range of plaque types and therapeutic interventions.
    • Comprehensive cardiovascular event prevention necessitates strategies targeting both lipid-rich and non-lipid-rich plaques, as well as destabilized lesions.
    • Multiple drug classes, beyond lipid-lowering agents, contribute to reducing cardiovascular events, potentially via plaque stabilization mechanisms.